ReviewFrontiers in endocrinology2018
Pituitary-Directed Therapies for Cushing's Disease.
Review in Frontiers in endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- A Case of Adrenocorticotropin-dependent Cushing Syndrome with Osilodrostat Exposure in Early Pregnancy.JCEM case reports · 2025Article
- Osilodrostat Safety Profile: Findings from Real-World Data in the FAERS Database.Journal of clinical medicine · 2025Article
- Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.Drug design, development and therapy · 2023Review
- The diagnosis and management of Cushing's syndrome in pregnancy.Journal of neuroendocrinology · 2022Review
- Recent Understanding and Future Directions of Recurrent Corticotroph Tumors.Frontiers in endocrinology · 2021Review
- Cushing's Disease.Journal of clinical medicine · 2019Review
- Review
- Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies.European endocrinology · 2019Review
- Beetles as Model Organisms in Physiological, Biomedical and Environmental Studies - A Review.Frontiers in physiology · 2019Review
- Article
- Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.Frontiers in endocrinology · 2019Article
- Cell Cycle Regulators and Lineage-Specific Therapeutic Targets for Cushing Disease.Frontiers in endocrinology · 2018Review
- THE MULTIFARIOUS CUSHING'S - LESSONS FROM A CASE SERIES.Acta endocrinologica (Bucharest, Romania : 2005)Article
- Osilodrostat for Cyclic Cushing Disease.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cushing's disease (CD) is caused by a pituitary corticotroph neuroendocrine tumor inducing uncontrolled hypercortisolism. Transsphenoidal surgery is the first-line treatment in most cases. Nonetheless, some patients will not achieve cure even in expert hands, others may not be surgical candidates and a significant percentage will experience recurrence. Many patients will thus require medical therapy to achieve disease control. Pharmacologic options to treat CD have increased in recent years, with an explosion in knowledge related to pathophysiology at the molecular level. In this review, we focus on medications targeting specifically pituitary adrenocorticotropic hormone-secreting tumors. The only medication in this group approved for the treatment of CD is pasireotide, a somatostatin receptor ligand. Cabergoline and temozolomide may also be used in select cases. Previously studied and abandoned medical options are briefly discussed, and emphasis is made on upcoming medications. Mechanism of action and available data on efficacy and safety of cell cycle inhibitor roscovitine, epidermal growth factor receptor inhibitor gefitinib, retinoic acid, and silibinin, a heat shock protein 90 inhibitor are also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.